Related Experiment Videos
Reduced neutral DNase activity in the urine of children after cytostatic therapy
Abstract:
In children with cancer a reduced neutral urine DNase activity was observed at the end of cytostatic therapy. It is presumed that disorders in the kidney functions are the cause. A low neutral DNase activity is found in the blood; the activity is inhibited by inhibitors. The inhibitors of the enzyme are split away in the kidneys so that the neutral DNase activity in urine increases. Many cytostatic drugs can induce damage to the kidneys. This may be the reason that not all inhibitors of neutral DNase are split away in the kidneys and the activity of the neutral urine DNase is reduced at the end of cytostatic therapy. The process of removing the inhibitors is independent of the filtering capacity of the kidneys.
Insights
Cytostatic therapy in children with cancer can reduce neutral urine deoxyribonuclease (DNase) activity, potentially due to kidney damage affecting enzyme inhibitor clearance. This finding suggests a link between kidney function and DNase activity during cancer treatment.
Area of Science:
- Biochemistry
- Pediatric Oncology
- Nephrology
Background:
- Reduced neutral urine deoxyribonuclease (DNase) activity is observed in children with cancer post-cytostatic therapy.
- This reduction is hypothesized to stem from impaired kidney function affecting DNase inhibitor processing.
Purpose of the Study:
- To investigate the relationship between cytostatic therapy, kidney function, and neutral urine DNase activity in pediatric cancer patients.
- To explore the role of enzyme inhibitors in the observed decrease of neutral urine DNase activity.
Main Methods:
- Analysis of neutral urine DNase activity in pediatric cancer patients before and after cytostatic therapy.
- Assessment of blood DNase activity and presence of DNase inhibitors.
- Evaluation of kidney function in relation to DNase inhibitor clearance.
Main Results:
- A significant decrease in neutral urine DNase activity was noted at the conclusion of cytostatic treatment.
- Blood DNase activity was low and inhibited by specific inhibitors.
- Kidney damage induced by cytostatic drugs may impair the removal of DNase inhibitors, leading to reduced urine DNase activity.
- The inhibitor removal process appears independent of the kidneys' overall filtering capacity.
Conclusions:
- Cytostatic therapy can compromise kidney function, leading to reduced clearance of DNase inhibitors.
- This impaired inhibitor clearance results in lower neutral urine DNase activity in pediatric cancer patients undergoing treatment.
- Monitoring urine DNase activity could offer insights into kidney function during cancer therapy.